Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Current Liabilities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Total Current Liabilities for 4 consecutive years, with $18.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 88.42% year-over-year to $18.1 million, compared with a TTM value of $18.1 million through Sep 2025, down 88.42%, and an annual FY2024 reading of $134.6 million, down 5.38% over the prior year.
  • Total Current Liabilities was $18.1 million for Q3 2025 at Atara Biotherapeutics, up from $14.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $180.7 million in Q1 2024 and bottomed at $14.6 million in Q2 2025.
  • Average Total Current Liabilities over 4 years is $92.1 million, with a median of $78.9 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities skyrocketed 166.21% in 2024, then crashed 90.18% in 2025.
  • Year by year, Total Current Liabilities stood at $78.9 million in 2022, then soared by 80.22% to $142.2 million in 2023, then fell by 5.38% to $134.6 million in 2024, then crashed by 86.58% to $18.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for ATRA at $18.1 million in Q3 2025, $14.6 million in Q2 2025, and $47.9 million in Q1 2025.